Calendar

An AMCP AI LINK Group Webinar.

AI is everywhere—but separating buzz from practical value is the hard part. In this webinar, we’ll tackle common misconceptions, walk through real examples, and explore how organizations can use AI more effectively across workflows and decision-making. Attendees will leave with a sharper understanding of where AI can make an impact today—and what it takes to use it well.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Vertex.

IgA nephropathy is a rare, progressive, B cell-driven kidney disease associated with clinical and economic burden. This webinar will review IgA nephropathy disease burden, unmet need, the recently updated 2025 KDIGO guidelines, and interim clinical outcomes from the Phase 1/2 and 3 trials of povetacicept, an investigational product from Vertex Pharmaceuticals that is being evaluated for the treatment of adults with IgA nephropathy. The safety and effectiveness have not been established.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar you must be registered as a user of FormularyDecisions. 

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

An AMCP Member Webinar.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Revolution Medicines.

Revolution Medicines will present results from the Phase 3 RASolute 302 study evaluating daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, in previously treated patients with metastatic pancreatic adenocarcinoma (PDAC). The PIE presentation will feature an overview of PDAC disease background, current second-line standard of care, and RASolute 302 study design elements and data.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

Join us as AMCP Market Insights shares exclusive findings from our recent multi-stakeholder expert roundtable on treatment-resistant depression. This webinar will break down payer perspectives on clinical data, address the looming provider network shortage, and outline actionable strategies to prepare your behavioral health network for these emerging interventional treatments. Attendees will walk away with concrete recommendations on removing care barriers, updating coverage frameworks, and driving cross-industry collaboration to evaluate, cover, and operationalize these therapies safely and effectively.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Incyte.

This PIE webinar on tafasitamab-cxix + lenalidomide + R-CHOP in Frontline DLBCL will cover disease state and epidemiology, the current treatment landscape, and key clinical/safety data, followed by a brief Q&A

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

This webinar brings together a clinical genetics expert and a managed care medical director to examine Barth syndrome, its mitochondrial mechanism, and the evidence supporting elamipretide, alongside a candid discussion of the coverage and access questions ultra-rare therapies raise—from label interpretation and natural history comparators to value-based contracting and the broader question of how innovation in ultra-rare disease is funded. Participants will leave with a clearer understanding of how clinical realities in rare disease intersect with coverage policy, and where collaboration among manufacturers, clinicians, and payers can improve diagnosis, equitable access, and patient care.